TY  - JOUR
AU  - Bivona, Trever G.
PY  - 2017
TI  - Dividing and conquering the variation among variants in  EML4-ALK  lung cancer
JF  - Translational Cancer Research; Vol 6, Supplement 2 (March 31, 2017): Translational Cancer Research
Y2  - 2017
KW  - 
N2  - Activating gene rearrangements in the anaplastic lymphoma kinase are present in approximately 2–7% of lung adenocarcinomas (ALK + cancers) (1,2). Patients with ALK + lung adenocarcinoma often benefit from treatment with an ALK tyrosine kinase inhibitor (TKI), such as crizotinib, ceritinib, and alectinib (2). However, acquired ALK TKI resistance remains an obstacle to long-term patient survival in patients who do respond to initial therapy and a distinct subset of ALK + patients fails to experience an initial tumor regression, exhibiting intrinsic resistance (2). Identifying the basis of both innate and acquired resistance is essential to improve clinical outcomes.
UR  - https://tcr.amegroups.org/article/view/12644